Marcella Origgi (PhD) is the Chief Executive Officer of Valo Therapeutics. She brings extensive experience across immunology, oncohematology, rare inherited diseases, precision medicine and advanced therapy medicinal products (ATMPs).
Before joining ValoTx, Marcella worked at Johnson & Johnson Innovation, where she was responsible for sourcing external innovation opportunities across oncology, immunology, rare diseases, and ATMPs. Her role involved asset development, due diligence, IP evaluation, public funding landscaping, remote scouting tool evaluation, and partnership development. She also served as a spokesperson at international events and represented J&J Innovative Medicine Italy at Farmindustria Ricerca & Innovazione.
Earlier in her career, Marcella held several roles at Janssen, including as Scientific & Patients Advocacy Groups Manager and as MSL Champion in the Immunology Medical Affairs Department. In these roles, she led and supported medical strategy, clinical trial feasibility, market access planning, and advisory board coordination for therapies including ustekinumab, guselkumab, golimumab, and sirukumab.
Marcella holds a PhD in Biology from the University of Milan, where she attended the Department of Pharmacology and Toxicology. She also holds additional qualifications in Intellectual Property and Trademarks, drug discovery and commercialization, and leadership programmes developed in collaboration with SDA Bocconi and Milan Polytechnic.
